## SPECIALTY QUANTITY LIMIT PROGRAM

# SIGNIFOR (pasireotide)

#### **PROGRAM DESCRIPTION**

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

### **II. COVERED QUANTITIES**

Medication	Standard Limit	FDA-recommended dosing
Signifor (pasireotide) subcutaneous injection 0.3 mg/mL	60 per 30 days	Recommended initial dosage: 0.6 mg or 0.9 mg injection twice a day
Signifor (pasireotide) subcutaneous injection 0.6 mg/mL	60 per 30 days	Recommended dosage range is 0.3 mg to 0.9 mg twice a day based on response, tolerability, and adverse effects.
Signifor (pasireotide) subcutaneous injection 0.9 mg/mL	60 per 30 days	

#### **III. REFERENCES**

1. Signifor [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2019.

Specialty Quantity Limit Signifor 2567-H P2019

© 2019 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of